Trial Profile
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Solithromycin (Primary) ; Solithromycin (Primary) ; Amoxicillin; Amoxicillin; Amoxicillin; Azithromycin; Ceftriaxone; Erythromycin; Erythromycin ethylsuccinate; Erythromycin lactobionate
- Indications Community-acquired pneumonia
- Focus Adverse reactions; Registrational
- Sponsors Cempra Pharmaceuticals; Melinta Therapeutics
- 01 Jul 2022 Results published in the Pediatric Infectious Disease Journal
- 29 May 2018 Status changed from recruiting to discontinued as development not proceeding
- 06 Nov 2017 According to Melinta Therapeutics media release, Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics.